Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News Can Merck rebuild its cardiovascular empire post-Keytruda? A closer look at its next decade of drug growth With Keytruda’s patent expiry nearing, Merck is betting on enlicitide and sotatercept to build a new cardiovascular empire. Can it succeed? byPallavi MadhirajuJune 10, 2025